Terkko Navigator / European Urology

Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel

Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset

Congress Calendar

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities

Reply to Jochen Walz. Let's Keep It at One Step at a Time: Why Biparametric Magnetic Resonance Imaging Is Not the Priority Today. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.028: How to Implement High-quality, High-volume Prostate Ma

Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti’s Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prosta

Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review And Meta-analysis. Eur Urol. In press. https://doi.org/10.

The Prevalence of Y-chromosome Microdeletions in Oligozoospermic Men: A Systematic Review and Meta-analysis of European and North American Studies

Perspectives on a Global Change in Testicular Cancer Incidence

The Finnish Randomized Trial of Adjuvant Radiotherapy Versus Observation After Prostatectomy: Almost a Trial of Adjuvant Versus Late Salvage Radiotherapy

Impact of Three-dimensional Printing in Urology: State of the Art and Future Perspectives. A Systematic Review by ESUT-YAUWP Group

Evolution of Robot-assisted Partial Nephrectomy: Techniques and Outcomes from the Transatlantic Robotic Nephron-sparing Surgery Study Group

Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice?

Congress Calendar

Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer

Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eu

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract

Congress Calendar

Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Ce

Re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.

Reply to Byung Kwan Park's Letter to the Editor re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol.

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667–75: How Does Circulating DNA Reach the Blood Stream?

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer

Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer

Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in

High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility

Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766–72. Partial Nephrectomy: “Geocentrism” of th

Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and

Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766–72: Partial Nephrectomy: “Geocentrism” of the 21st century in the Church of Urology?

Re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846–52

“Ride the Green Light”: Indocyanine Green–marked Off-clamp Robotic Partial Nephrectomy for Totally Endophytic Renal Masses

Acknowledgement to Reviewers

Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors

Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019

Should We Really Screen for Genital Variants Before Birth?

Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. In press.

Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question

Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy

Transvaginal Repair of Apical Vesicovaginal Fistula: A Modified Latzko Technique—Outcomes at a High-volume Referral Center

Re: Use of Prostate Systematic and Targeted Biopsy on the Basis of Multiparametric MRI in Biopsy-naive Patients (MRI-FIRST): A Prospective, Multicentre, Paired Diagnostic Study

Overactive Surveillance: Is “Conservative” Management for Low-risk Prostate Cancer Too Aggressive?

Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom

Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses

Reply to Pablo Sierra's Letter to the Editor re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol. In press. https://doi.org/10.101

Reply to Satoru Taguchi, Tohru Nakagawa, and Hiroshi Fukuhara's Letter to the Editor re: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy:

Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer